Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.

导出 LinkOut

翻译打印收藏纠错

作者： Sebastian K,Eder ^[1] ; Raphaela,Schwentner ^[2] ; Philipp,Ben Soussia ^[2] ; Giulio,Abagnale ^[2] ; Andishe,Attarbaschi ^[3] ; Milen,Minkov ^[4] ; Florian,Halbritter ^[2] ; Caroline,Hutter ^[1]

作者单位： St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.;St. Anna Children's Cancer Research Institute, Vienna, Austria; and. ^[1] St. Anna Children's Cancer Research Institute, Vienna, Austria; and. ^[2] St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. ^[3] St. Anna Children's Cancer Research Institute, Vienna, Austria; and.;Klinik Floridsdorf, Department of Pediatrics, Neonatology and Adolescent Medicine, Vienna, Austria. ^[4]

主题词细胞因子类(Cytokines);组织细胞增多症, 郎格尔汉斯细胞(Histiocytosis, Langerhans-Cell);人类(Humans);炎症(Inflammation);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf)

DOI 10.1182/bloodadvances.2021005442

PMID 34619771

发布时间 2024-08-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Blood advances

2022年6卷3期

970-975页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除